Expert Interview
Understanding the future of Vertex Pharma's “Vanza Triple” (vanzacaftor/tezacaftor/deutivacaftor) in patients with Cystic Fibrosis (CF)
Ticker(s): VRTXInstitution: UCLA School of Medicine
- Professor of Medicine and Pulmonology at UCLA
- Medical Director of the Lung Institute at Cedars Sinai who has experience managing patients with the Zephyr and Spiration valve. Sees 200 patients with COPD and emphysema
- Research interest in pulmonary exercise physiology, hyperinflation, emphysema and non-invasive lung volume reduction in emphysema.
Describe your background and practice setting
Added By: ben_adminHow many CF patients do you manage?
Added By: ben_adminWhat is the current standard of care for CF?
Added By: ben_adminWhat is your opinion on the potential of the Vanza triple from Vertex? Where would it fit into your treatment approach?
Added By: ben_adminWhat is your level of excitement for the Vanza triple on a scale of 1-10?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
